2017 Annual and Sustainability Report
"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field", says Guido Oelkers, CEO.
Annual General Meeting 2018
The Annual General Meeting was held on Wednesday, May 9, 2018 at 15:00 at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
Data presented at ASH support emapalumab as an innovative, targeted therapeutic option for primary HLH
12/04/2018 - 01:30
At ASH, extended half-life therapies Elocta® and Alprolix® demonstrate proven efficacy and well-characterised safety over four years
12/01/2018 - 17:00
Late-breaking abstract at ASH supports evidence on transformative first-ever treatment in primary HLH
11/22/2018 - 13:00
FDA approves Gamifant® (emapalumab), the first and only treatment for primary haemophagocytic lymphohistiocytosis (HLH)
11/20/2018 - 15:29